Clinical trial
A Study Measuring Effects on Intima Media Thickness: An Evaluation of…
NCT00225589 · AstraZeneca, Industry · Completed
Key facts
| NCT number | NCT00225589 |
|---|---|
| Title | A Study Measuring Effects on Intima Media Thickness: An Evaluation of Rosuvastatin 40 mg (METEOR) |
| Official title | A Randomized, Double-blind, Placebo-controlled, Multicenter Parallel Group Phase III Study Measuring Effects on Intima Media Thickness: an Evaluation Of Rosuvastatin 40 mg (METEOR) |
| Lead sponsor | AstraZeneca, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Hypercholesteremia |
| Intervention type | Drug |
| Interventions | Rosuvastatin calcium |
| Enrollment | 840 |
| Start date | Aug 1, 2002 |
| Primary completion | May 1, 2006 |
| Completion | May 1, 2006 |
| First posted | Sep 26, 2005 |
| Last update posted | Nov 19, 2010 |
| Countries | Belgium, Czechia, Finland, France, Germany, Netherlands, Norway, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: